Drug Action
Nimodipine is a dihydropyridine calcium- channel blocker.
Source page 144
Loading InternPractice…
Individual generic drug information
Extracted information for Nimodipine only.
Nimodipine is a dihydropyridine calcium- channel blocker.
Source page 144
Prevention of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage ▶BY MOUTH ▶Adult: 60 mg every 4 hours, to be started within 4 days of aneurysmal subarachnoid haemorrhage and continued for 21 days Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage ▶BY INTRAVENOUS INFUSION ▶Adult (body-weight up to 70 kg): Initially up to 0.5 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter ▶Adult (body-weight 70 kg and above): Initially 1 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage in patients with unstable blood pressure ▶BY INTRAVENOUS INFUSION ▶Adult: Initially up to 0.5 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter
Source page 144
Unstable angina. within 1 month of myocardial infarction
Source page 144
Cerebral oedema. hypotension. severely raised intracranial pressure
Source page 144
Extracted information for Nimodipine only.
SAFE PRACTICE Nimodipine has been confused with amlodipine; care must be taken to ensure the correct drug is prescribed and dispensed.
Source page 144
→Appendix 1: calcium channel blockers
Source page 144
▶Uncommon Thrombocytopenia. vasodilation ▶Rare or very rare Bradycardia. ileus
Source page 144
Manufacturer advises use only if potential benefit outweighs risk.
Source page 145
Manufacturer advises avoid—present in milk.
Source page 145
▶With oral use Manufacturer advises consider avoiding in severe impairment. Dose adjustments ▶With oral use Manufacturer advises dose reduction, if used in severe impairment.
Source page 145
Monitoring ▶With intravenous use Manufacturer advises monitor renal function closely in renal impairment.
Source page 145
Extracted information for Nimodipine only.
Avoid concomitant administration of nimodipine infusion and tablets. ▶With oral use For administration by mouth, tablets may be crushed or halved but are light sensitive—administer immediately. ▶With intravenous use For intravenous infusion, give via drip tubing in Glucose 5% or Sodium chloride 0.9%. Not to be added to infusion container; administer via an infusion pump through a Y-piece into a central catheter; incompatible with polyvinyl chloride giving sets or containers; protect infusion from light. ▶With intravenous use Polyethylene, polypropylene, or glass apparatus should be used.
Source page 145
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension Solution for infusion ▶Nimotop (Bayer Plc) Nimodipine 200 microgram per 1 ml Nimotop 0.02% solution for infusion 50ml vials | 1 vial P £13.60 (Hospital only) Tablet ▶Nimotop (Bayer Plc) Nimodipine 30 mg Nimotop 30mg tablets | 100 tablet P £40.00 DT = £40.00 Blood clots 3.1 Blocked catheters and lines Other drugs used for Blocked catheters and lines Heparin (unfractionated), p. 143. Urokinase, p. 148 PROSTAGLANDINS AND ANALOGUES
Source page 145
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
60 mg every 4 hours, to be started within 4 days
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 144
First line only; read the complete Indications and dose section above.
Initially up to
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 144
First line only; read the complete Indications and dose section above.
Initially 1 mg/hour,
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 144
First line only; read the complete Indications and dose section above.
Initially up to 0.5 mg/hour, increased after
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 144